Aminolevulinic acid - Medac

Drug Profile

Aminolevulinic acid - Medac

Alternative Names: 5-ALA - Medac; 5-ALA - Photonamic; 5-ALA Patch; Alacare; Aminolevulinic acid HCl; Effala; Gliolan; PD P 506 A; PD P 506 A-PDT

Latest Information Update: 06 Sep 2016

Price : $50

At a glance

  • Originator Photonamic
  • Developer LINK Healthcare; Medac; Photonamic; Specialised Therapeutics Australia; Spirig Pharma
  • Class Amino acids; Antineoplastics; Keto acids; Levulinic acids; Oxidants; Skin disorder therapies; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Actinic keratosis; Glioma
  • Phase II Onychomycosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 22 Nov 2015 Launched for Actinic keratosis in Australia (Topical)
  • 18 Sep 2015 Registered for Glioma (Diagnosis) in New Zealand (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top